



Tuberculosis (TB) is a serious worldwide health problem 
that can cause illness in millions of people.[1] It is a 
prominent cause of death in persons living with human 
immunodeficiency virus (HIV) infection and also a 
leading cause of death from a single transmissible disease 
agent.[1] In 2017, an estimated 10 million incident cases of 
TB (133 cases/100,000 populace) and 1.6 million TB deaths 
occurred. TB epidemiology varied by the World Health 
Organization (WHO) regions.[2] The African and South-East 
Asia regions accounted for nearly 70% of the overall global 
TB burden. Six countries, namely India, Indonesia, China, 
Nigeria, Pakistan, and South Africa account for 60% of all 
new cases, and Nigeria was rated 4th among the countries 
with the greatest burden of the disease.[3]
Directly observed treatment short course (DOTS) is one of the 
globally endorsed control strategies for TB. It was initiated by 
the WHO to drastically reduce poor drug adherence, treatment 
dropout rates, and achieve a cure rate of at least 85%.[4,5] The 
Introduction: Although concerted efforts have been implemented to achieve tuberculosis (TB) prevention and control, varying outcomes have 
been reported in several quarters, despite the implementation of the directly observed treatment short-course (DOTS) strategy in virtually all 
parts of the world. It was considered necessary to assess the treatment outcomes of TB patients on DOTS strategy and the associated factors 
against the World Health Organization (WHO) target at the University of Port Harcourt Teaching Hospital (UPTH) Port Harcourt, to stimulate 
improvements in efforts toward patients care in the hospital and elsewhere. Methods: A health facility-based review of patients’ records (January 
1, 2014–December 31, 2018) at the TB Clinic of UPTH was carried out using a validated data record sheet. Patients undergoing treatment were 
excluded. Data were analyzed with the SPSS software version 20. Outcome frequencies were summarized, and the Pearson’s Chi-square test 
was used to determine the association between the outcome and independent variables at P ≤ 0.05 statistical significance level. Results: Overall, 
174 (25.7%) had completed treatment, 181 (26.7%) were cured, 95 (14.0%) died, 70 (10.3%) transferred out, 45 (6.6%) defaulted, 49 (7.2%) 
were not evaluated, 44 (6.5%) were lost to follow-up, and 8 (1.2%) failed treatment. There was a 17.6% decline in the proportion of patients that 
completed treatment from 35.9% in 2014 to 18.3% in 2018. On the contrary, there was an increase in the proportion of patients that were cured, 
from 14.1% in 2014% to 26.1% in 2018. Conclusions: The treatment success rate for TB in the hospital was below the WHO benchmark of 
85% cure rate throughout the period under review. Basic reforms in the service delivery processes that specifically targets groups at risk (male 
patients, sputum smear-negative TB patients, and patients with human immunodeficiency virus/TB co-infection) with drug adherence counselling, 
defaulter tracing arrangements, and emphasis on drug-susceptibility testing are recommended to improve treatment outcomes.
Keywords: Directly observed treatment short-course, Nigeria, Rivers State, tuberculosis treatment, tuberculosis outcomes
Address for correspondence: Dr. Vivian Ifeoma Ogbonna, 
Department of Community Medicine, University of Port Harcourt Teaching 
Hospital, Port Harcourt, Nigeria. 
E-mail: viogbonna@gmail.com
This is an open access journal, and articles are distributed under the terms of the Creative 
Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to 
remix, tweak, and build upon the work non‑commercially, as long as appropriate credit 
is given and the new creations are licensed under the identical terms.
For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com
How to cite this article: Ogbonna VI, Alabere DI, Tobin-West CI. Treatment 
outcomes and associated factors of tuberculosis patients on directly observed 
treatment (short course) in a tertiary hospital in Port Harcourt, Nigeria. 
Niger J Med 2020;29:707-13.
Submitted: 18-May-2020 Revised: 31-Aug-2020
Accepted: 29-Oct-2020 Published: 24-Dec-2020
Treatment Outcomes and Associated Factors of Tuberculosis 
Patients on Directly Observed Treatment (Short Course) in a 
Tertiary Hospital in Port Harcourt, Nigeria
Vivian Ifeoma Ogbonna1, David Ibidabo Alabere1,2, Charles Ibiene Tobin-West1,2
1Department of Community Medicine, University of Port Harcourt Teaching Hospital, 2Department of Preventive and Social Medicine, College of Health Sciences, 
University of Port Harcourt, Port Harcourt, Nigeria






© 2020 Nigerian Journal of Medicine | Published by Wolters Kluwer - Medknow 707
Ogbonna, et al.: Tuberculosis treatment outcomes in a tertiary hospital
primary objective of the strategy was to ensure that a patient 
takes the TB drug in the presence of a health worker or a 
designated treatment supporter, who might be a family or 
community member.[6] This is because in resource-limited 
settings such as Nigeria, despite the free treatment, daily 
medications for a minimum period of 6 months poses a 
challenge to many patients.
With a successful DOTS strategy in place, the WHO estimates 
that the incidence of TB ought to be on the decline at a rate 
of 10% per year by 2025, and the proportion of people with 
TB who die from the disease will fall to about 6.5% by 
2025.[7] Other possible treatment outcomes include treatment 
completed, treatment failure, died, lost to follow-up, not 
evaluated, moved to second-line for drug treatment, and 
treatment success rate. According to the Nigerian National 
TB and Leprosy Control Programme guideline,[8] the outcome 
categories are defined as follows:
a. Cured: Initially, a smear-positive patient who completed 
treatment and had negative bacteriology result on at least 
two times, one of which is after treatment
b. Completed treatment: Finished treatment, but without 
bacteriology result at the end of the treatment
c. Treatment failure: Remaining smear-positive at five 
months despite the correct intake of medication
d. Defaulted treatment: Patients who interrupted their 
treatment for two consecutive months or more of registration
e. Died: Patients who died from any cause during the course 
of treatment
f. Transferred-out: Patients whose treatment results are 
unknown due to transfer to another health facility
g. Successfully treated: A patient who was cured or 
completed treatment
h. Not evaluated: A patient whose laboratory assessment was 
not done at the end of treatment, and as such no outcome 
was assigned.[8]
Unsuccessful treatment outcome refers to the treatment of 
TB patients that resulted in treatment failure, i.e., remains 
smear-positive after five months of treatment, default (patients 
who interrupted their treatment for two consecutive months 
or more after registration), or died.[1,9] Although many local, 
regional, and international efforts have been implemented to 
achieve TB prevention and control, TB patients are still failing 
to complete treatment and be declared cured even with the 
institution of the globally recommended (DOTS) strategy in 
virtually all parts of the world. According to the WHO report of 
2018, all over the world, a significant proportion of TB patients 
has not recovered after several courses of treatments. Some of 
the obstacles are relapsing after completion of the treatment, 
defaulting from treatment, and developing multi-drug-resistant 
TB (MDR-TB) among retreatment cases.[7,10] Nevertheless, 
a study done in Southern Ethiopia indicated that DOTS 
improved the TB treatment outcomes and service coverage 
thereby averting new infections and the emergence of drug 
resistance.[10] Some studies in Nigeria have shown varying 
outcomes and treatment success rates.[11]
Although the TB Clinic of the University of Port Harcourt 
Teaching Hospital (UPTH) has been operational for several 
decades, there has been no documented report on the outcome 
of services rendered to TB patients. It is against this background 
that it was deemed necessary to assess the treatment outcomes 
and the associated factors of TB patients on the DOTS strategy 
at the UPTH to weigh the clinic’s performance against the 
WHO target of 85% cure rate or successful treatment rate. The 
outcome of the study is also expected to stimulate interests and 




The study was done at the DOTS Clinic of the UPTH, one 
of the two tertiary health-care institutions in Port Harcourt, 
the capital of Rivers State, South-south Nigeria. The hospital 
is a 950-bed health facility that offers tertiary health-care 
services, secondary and primary health care.[12] The TB clinic 
is domiciled in the Endemic Disease Unit of the Department 
of Community Medicine. The patients are generally referred 
from Port Harcourt and its environs, the Family Medicine 
Department, Accident and Emergency Department, referrals 
from the medical wards (male or female), children’s ward, 
and the anti-retroviral clinic. The staff included the consultant 
community physicians, resident doctors, nurses, staff of 
voluntary agencies like the Family Health International 
and Health Assistants. Drug supply is from the Rivers State 
Ministry of Health. Diagnosis is made using patient history, 
medical examination, and laboratory finding (sputum acid-fast 
bacilli [AFB], culture, and GeneXpert). The patients are 
monitored with sputum samples taken at 2, 5, and 7 months, 
respectively, for AFB after the commencement of treatment 
and results recorded in a monitoring card.
Study design
The study was a health facility-based, descriptive review of 
patient records at the TB Clinic of the UPTH, Port Harcourt.
Study population
The present study was based on the facility records of all TB 
patients registered at the DOTS Clinic between the period 
under review.
Inclusion/exclusion criteria
The records of all cases of pulmonary TB and extrapulmonary 
TB registered at the DOTS Clinic of UPTH between January 1, 
2014 and December 31, 2018, as well as all cases transferred in 
and re-treatment cases were included in the study. Nevertheless, 
all patients undergoing treatment were excluded.
Sampling and sample size determination
All case files of TB patients registered at the DOTS Clinic of 
UPTH from January 1, 2014, to December 31, 2018 that met 
the inclusion criteria were included in the study. The patient 
files/records were reviewed for completeness before inclusion. 
The minimum sample size was derived based on the Cochran’s 
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formula for sample size calculation for the descriptive study,[13] 
using an estimate of the treatment success rate of 60.1%[1] 
and providing for a further 20% allowance to compensate for 
incompletely filled case files.
The formula was: n = Z2pq/e2, where n = minimum sample size for 
the study; Z = the normal curve, 1.96 at 95% confidence interval; 
e = margin of precision (5%); P = 60.1%, prevalence estimate 
of treatment success of 60.1%; q = 1 − p. After computation, a 
sample size estimate for the study of 461 was arrived at.
Study instrument
Data were collected using a data extraction sheet which had the 
following sections: Section A: Sociodemographic characteristics 
of patients and year of treatment; Section B: Anthropometry 
attributes of patients (weights before commencement of treatment, 
at the end intensive phase of treatment, and at completion of 
treatment); and Section C: Laboratory results of patients (Type of 
TB by outcome of by bacterial culture, Case type, Disease location, 
Patient categories during the start of treatment, HIV status and 
GeneXpert result). For type of TB bacterial culture status (smear), 
there were 1+, 2+, or 3+, negative or unknown. Those classified 
as unknown were those diagnosed based on clinical judgment 
of the physicians, WHO score for children, chest X-ray results, 
or computed tomography scan, or magnetic resonance imaging 
reports. The case types were either new or re-treatment cases. 
Disease location was either pulmonary or extrapulmonary TB. 
Treatment categories (CAT) were CAT1, CAT 2, R-6 (6  months 
regimen) or R-12 (12  months regimen). The HIV status of patients 
was either HIV positive on anti-retroviral therapy (ART), HIV 
positive, but not on ART, HIV negative or unknown HIV status. 
Gene Xpert results were rated as: Not detected, detected, or not 
done. Section D: Treatment outcomes (cured, treatment completed, 
treatment failure, died, lost to follow-up, not evaluated, moved to 
a second line, and treatment success).
Study procedure/data collection process
Data were collected by the authors using a structured data 
extraction sheet designed for the study. The period under review 
covered from January 1, 2014, to December 31, 2018. Pertinent 
patient data from the year of treatment commencement, age, 
gender, residence, type of TB, smear results at baseline, HIV 
status, patient category during the start of treatment, and the 
outcomes of treatment were extracted from the case files and 
the treatment registers.
Data analysis
Data were entered into MS Excel spreadsheet and then 
exported into SPSS software version 20. Descriptive statistics 
were used to generate and summarize the outcome frequencies. 
Pearson’s Chi-square test was used to determine the association 
between treatment outcome and independent variables. The 
level of statistical significance was set at P ≤ 0.05.
Validity/reliability
Face validity of the data extraction tool was done to ensure 
that it measured what it intends to measure.
Ethical considerations
Approval was sought and obtained from the Research and 
Ethics Committee of the University of Port Harcourt (UPH/
CEREMAD/REC/MM61/054). Permission to conduct the 
study was also sought and obtained from the UPTH.
Limitations of the study
This was based on the records of TB patients’ case files 
and registers. It was not feasible to independently verify 
the accuracy of these records nor was it possible to collect 
additional data needed to confirm or refute the findings. 
However, since the findings were based on routine/regular 
data, it reflected the operational reality of the facility. Some 
information was missing from the case files.
Results
The number of cases that met the inclusion criteria and 
included in the study according to the year was as follows: 
2014 (128 cases), 2015 (195 cases), 2016 (115 cases), 
2017 (124 cases), and 2018 (115 cases), respectively, 
bringing the number to a total of 677. The present study 
included all age groups and ranged from 6 weeks to 83 years. 
The majority (70.2%) of the patients were adults, and with 
29.8% in the pediatric age category. The mean age was 
28.95 years ± 19.3 years, and the standard error was 0.74. 
The median age was 31.00 years, and the interquartile range 
was 31.00 years. Out of the 677 cases under review within 
the period, the greater part 371 (54.8%) were males, and 
306 (45.2%) were females. By marital status: 127 (18.8%) 
were married, and 124 (18.3%) were widowed, 10 (1.5%) 
were divorced or separated from their partners. The marital 
status of 409 (60.4%) was not provided, and they were lumped 
along with children. Majority 465 (68.7%) of the patients 
lived in the urban areas of the state, whereas 212 (31.3%) 
lived in the rural areas. According to occupations, there were 
several missing records, especially for the years 2014, 2015, 
and some parts of 2016 totalling, 389. For those recorded, 
110 (38.2%) of the patients were self-employed (as artisans, 
fishing, farming, trading, and business), whereas 102 (34.4%) 
were unemployed (mainly students and homemakers) and 
76 (26.4%) were employed [Table 1].
Overall, during the 5-year period under review, 174 (25.7%) 
had completed treatment, 181 (26.7%) were cured, 95 (14.0%) 
died, 70 (10.3%) transferred out, 45 (6.6%) defaulted, 
49 (7.2%) were not evaluated, 44 (6.5%) were lost to follow-up, 
and 8 (1.2%) failed treatment. There was a 17.6% decline in the 
proportions of patients that completed treatment from 35.9% in 
2014 (46 of 128 patients) to 18.3% in 2018 (21 of 115 patients). 
On the contrary, there was an increase in the proportions of 
patients that were cured, from 14.1% in 2014 to 26.1% in 
2018. There was no significant change in the proportion of 
patients that met the criteria for treatment failure over the years 
under review. Although there appeared to be a decline in the 
proportions of patients who defaulted in receiving treatment, 
there was also an increase in the proportion of those that were 
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not evaluated at the end of the treatment period (none in 2014, 
but 37.4% in 2018). There was also an overall increase in the 
proportions of patients that were lost to follow-up from none 
in 2014 to 12.1% in 2017, but this figure dropped to 4.3% in 
2018 [Table 2].
From the evaluation, 355 (52.4%) had a successful treatment 
outcome in the hospital, against 322 (47.6%) unsuccessful 
treatment outcome. At no point during the period under 
review did the treatment success rate, meet or exceed the 
WHO recommendation of 85%. The highest rate of treatment 
success (67%) was achieved in 2016 [Table 3].
There was a significant relationship between age, gender, 
and treatment outcomes. In the age category of 21–40 years, 
163 (61.0%) of the patients had a successful treatment outcome, 
compared to the rest age categories (P = 0.002). The female 
gender, 174 (56.9%) more successful treatment outcome 
when compared with the male 181 (48.8%) (P = 0.036). Other 
sociodemographic variables such as residential area and marital 
status did not show any significant association [Table 4].
Disease-related factors such as the case type (new or 
retreatment case), sputum smear (positive or negative), 
and HIV status (positive or negative) had a significant 
relationship with treatment outcomes. Patients who underwent 
re-treatment for TB, 48 (65.8%) had successful treatment 
outcomes compared to new cases 307 (50.8%) (P = 0.016). 
The smear-positive TB (PTB) cases 136 (68.0%) had better 
treatment outcomes compared to smear-negative TB cases 
219 (45.9%) (P = 0.000). Patients with HIV-negative status, 
238 (59.6%) had more successful treatment outcomes 
compared to those with HIV-positive status 114 (43.5%) 
P < 0.01 [Table 5].
dIscussIon
The cumulative successful treatment outcome rate for all TB 
types of 52.4% reported in this study was very low compared 
to what has been reported in several studies in Nigeria and 
elsewhere[1] and also fell far short of the WHO recommended 
a target of 85%.[14] This poor outcome represents a huge 
challenge for patient survival and severe implication for the 
emergence and spread of MDR-TB in the state and its environs. 
The huge disparity in the outcomes could be partly attributed 
to the higher prevalence of TB/HIV co-infection in the index 
study of 38.7% when compared to a TB/HIV co-infection 
rate of 19.1% in a similar study in Ethiopia.[15] Nevertheless, 
the result calls for an urgent, focussed intervention to reduce 
defaulter rates, loss to follow-ups, and the proportion of 
patients not evaluated, as well as take a second look at the 
service delivery processes and programme contents of the TB 
clinic of the hospital.
Furthermore, the experience from our study shows that there 
was an inverse relationship with age and successful treatment 
outcomes because as the age of the patients increased, the 
proportion with successful treatment outcomes declined. This 
finding may be due to a higher loss to follow-ups, mortality, and 
Table 2: Treatment outcomes by year
Variable 2014 (%) 2015 (%) 2016 (%) 2017 (%) 2018 (%) Total (%)
Completed treatment 46 (35.5) 50 (25.6) 35 (30.4) 22 (17.7) 21 (18.3) 174 (25.7)
Cured 18 (14.1) 45 (23.1) 42 (36.5) 46 (37.1) 30 (26.1) 181 (26.7)
Treatment failure 2 (1.6) 4 (2.1) 0 2 (1.6) 0 8 (1.2)
Defaulted 35 (27.3) 10 (5.1) 0 0 0 45 (6.6)
Transferred 15 (11.7) 33 (16.9) 7 (6.9) 15 (12.1) 0 70 (10.3)
Died 12 (9.4) 33 (16.9) 17 (14.8) 19 15.3) 14 (12.2) 95 (14.0)
Loss to follow up 0 12 (6.1) 12 (10.4) 15 (12.1) 5 (4.3) 44 (6.5)
Not evaluated 0 4 (2.1) 0 2 (1.6) 43 (37.4) 49 (7.2)
Removed from treatment register 0 4 (2.1) 2 (1.7) 3 (2.4) 2 (1.7) 11 (1.6)
Total 128 (18.9) 195 (28.8) 115 (17.0) 124 (18.3) 115 (17.0) 677 (100)
Table 1: Sociodemographic profile of study participants
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Table 4: Association of between sociodemographic factors with treatment outcomes
Variable Treatment outcome Total χ2 P
Successful (%) (n=355) (52.4) Unsuccessful (%) (n=322) (47.6)
Age
0-20 109 (49.1) 113 (50.9) 222 (100.0) 17.307 0.002*
21-40 163 (61.0) 104 (39.0) 267 (100.0)
41-60 72 (47.1) 81 (52.9) 153 (100.0)
61-80 11 (32.4) 23 (67.6)  34 (100.0)
81-100 0 (0.0) 1 (100.0) 1 (100.0)
Gender
Male 181 (48.8) 190 (51.2) 371 (100.0) 4.385 0.036*
Female 174 (56.9) 132 (43.1) 306 (100.0)
Total 355 (52.4) 322 (47.6) 677 (100.0)
Occupation
Unemployed 65 (63.7) 37 (36.3) 102 (100.0) 3.370 0.185
Self-employed 63 (57.3) 47 (42.7) 110 (100.0)
Employed 38 (50.0) 38 (50.0) 76 (100.0)
Residential area
Rural 108 (50.9) 104 (49.1) 212 (100.0) 0.276 0.599
Urban 247 (53.1) 218 (46.9) 465 (100.0)
Total 355 (52.4) 322 (47.6) 677 (100.0)
Marital status
Married 77 (52.7) 69 (47.3) 146 (100.0) 5.444 0.352**
Single 77 (60.6) 50 (39.4) 127 (100.0)
Divorced/separated 4(57.1) 3 (42.9) 7 (100.0)
Widowed 5 (50.0) 5 (50.0) 10 (100.0)
Not recorded/child 192 (49.6) 195 (50.4) 387 (100.0)
Total 355 (52.4) 322 (47.6) 677 (100.0)*
*Statistically significant, **Fisher’s exact; level of significance for this study was set at P<0.05
Table 3: Two categories treatment outcome by year of treatment
Variable 2014 (%) 2015 (%) 2016 (%) 2017 (%) 2018 (%) Total (%)
Successful treatment 64 (50.0) 95 (48.7) 77 (67.0) 68 (54.8) 51 (44.3) 355 (52.4)
Unsuccessful treatment 64 (50.0) 100 (51.3) 38 (33.0) 56 (45.2) 64 (55.7) 322 (47.6)
Total 128 (18.9) 195 (28.8) 115(17.0) 124 (18.3) 115 (17) 677 (100)
severe morbidity associated with aging as has been reported 
in previous studies.[10,16] Again, this once more underscores 
the need to critically appraise and perhaps review the role of 
treatment supporters in the DOTS programme initiative of the 
hospital, which is designed to ensure that patients, especially 
the vulnerable ones get additional home and community-based 
support that could enhance their full recovery.
With respect to gender, a greater proportion of females 
compared to their male counterparts had better treatment 
outcomes. This finding corroborates that by Oyefabi et al. in 
Zaria, Nigeria.[17] This is expected as females are known to 
exhibit better health-seeking behaviors than males and adhere 
better to medications and advice of health-care providers.[18,19] 
There was also a significant relationship that reveals that 
re-treated TB cases had better treatment outcomes than new 
cases. This finding was very reassuring because it was a pointer 
that the adherence counseling of the TB clinic was possibly 
yielding the desired results. It might also be partially influenced 
by the drug-susceptibility testing which became commonly 
conducted to inform the choices of treatment regimens. 
However, the finding was at variance with some other studies 
that demonstrated unsuccessful treatment outcome among 
re-treated cases compared to new cases.[11]
There was also a significant relationship between sputum 
smear-PTB patients at presentation and treatment outcome, as 
smear-PTB patients had better treatment outcomes compared 
to sputum smear-negative TB patients. This finding is in 
agreement with that conducted in Ethiopia where smear-PTB 
patients had 3.204 times more successful treatment outcomes 
compared to smear-negative TB cases.[1] This is because 
many smear-negative patients might live with a false sense 
of recovery since their sputum test was negative results 
and become complacent with their medications, which 
might compromise their health outcome. In other situations, 
many smear-negative cases could be severely ill, with 
co-morbidities or immunocompromised with HIV, which 
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could result in despair and subsequent reluctance in taking 
their medications.
With regard to HIV status and association with treatment 
outcomes, more HIV-negative patients had better treatment 
outcomes than HIV-positive patients. This finding corroborates 
similar findings by other researchers.[15] This is probably 
because the HIV/TB co-infection, like most co-morbidities 
can be very emotionally tasking, and associated with additional 
pill burden/load, which could possibly negatively affect 
their medication adherence, thus leading to poor treatment 
outcomes.
conclusIons
It was obvious from the study that the treatment success 
rate for TB in the DOTS clinic was below expectation and 
the global standard as represented by the WHO benchmark. 
In light of this, there is a compelling need to institute some 
basic reforms in the service delivery processes, specifically 
targeting male patients, patients with HIV/TB co-infection, 
and sputum smear-negative patients with drug adherence 
counseling, defaulter tracing arrangements, and emphasis 
on drug-susceptibility testing for all patients are highly 
recommended.
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